People with moderate to severe obstructive sleep apnea may have an intrinsic inability to burn high amounts of oxygen during strenuous aerobic exercise according to a new study led by researchers at University of California, San Diego School of Medicine.
Global Obesity Epidemic is Linked to Gut Microbiome DNA Sequence-Based Microbiomes Accurately Associate with Obesity Blue Agave Margaritas Contain Beneficial Gut Microbes Investments in Microbiome-based Therapies on the Rise, but is there Hype? Last August, my post entitled Meet Your … Continue reading →
The post You and Your Microbiome – Part 2 appeared first on Zone in With Zon.
Be Thankful for the Little Things… and the big things that make the little things work I’ve said it before: […]
Article One Partners (AOP), the world’s largest online patent and technical literature research community is seeking immediate, part-time Technical Literature Researchers to support our growing inventory of technical and research studies [...]
“If we can find a way to target those neurons in humans, maybe we can reduce the ‘high’ produced by the drug and reduce the withdrawal symptoms,” says Assistant Professor Olivier George.
The new study from the Ward and Saphire labs exposes how experimental drug ZMapp attacks the virus and suggests strategies to improve future therapies.
The study from the Balch lab suggests diseases such as cystic fibrosis and Alzheimer’s can be seriously exacerbated by the body’s response, providing fundamental insights with implications for the design of new therapies.
Professor Hugh Rosen spoke to donors about his experiences with drug discovery at a recent lecture hosted by TSRI’s Office of Philanthropy.
Our client, a well-established biotechnology company located in Carlsbad, CA has a long-term, temporary, 5-month opportunity for an experienced Executive…
From CareerBuilder – 24 Nov 2014 13:08:03 GMT
– View all San Diego jobs
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2014 /PRNewswire/ – Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present in a fireside chat discussion at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014 at 12:30 p.m. ET in New York.
The live audio webcast and subsequent replay may be accessed by visiting Veracyte’s website at http://investor.veracyte.com. Please connect to the website at least 15 minutes prior to the live webcast to ensure adequate time for any necessary software download. The webcast will be available shortly after conclusion of the presentation and archived on the company’s website for 14 days following the presentation.
Veracyte (Nasdaq: VCYT) is pioneering the field of molecular cytology, focusing on genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte’s first commercial solution, the Afirma® Thyroid FNA Analysis, centers on the proprietary Afirma Gene Expression Classifier (GEC) to resolve ambiguity in diagnosis and is becoming a new standard of care in thyroid nodule assessment. Since launching its Afirma solution in 2011, Veracyte estimates it has helped approximately 10,000 patients with thyroid nodules avoid unnecessary surgery, reducing healthcare costs by millions of dollars. Afirma is recommended in leading practice guidelines and is covered for more than 135 million lives in the United States, including through Medicare and most commercial insurance plans. Veracyte intends to expand its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. The company is in late product development for a genomic test to resolve preoperative ambiguity in lung nodules that are suspicious for cancer. Veracyte is also developing a second product in pulmonology, targeting interstitial lung diseases that include idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.
Veracyte, Afirma, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc. This press release also contains trademarks and trade names that are the property of their respective owners.
Media:Tracy Morris650-380-4413 Tracy.Morris@Veracyte.com
Investors:Angeli KolhatkarBurns McClellan, Inc.firstname.lastname@example.org